Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
82 hedge funds and large institutions have $76.7M invested in Antares Pharma, Inc. in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 30 reducing their positions, and 14 closing their positions.
4% less funds holding
Funds holding: 85 → 82 (-3)
20% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 30
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
38% less capital invested
Capital invested by funds: $123M → $76.7M (-$46.2M)
96% less call options, than puts
Call options by funds: $14K | Put options by funds: $354K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$2.4M |
| 2 |
BC
Broadfin Capital
New York
|
+$1.42M |
| 3 |
Renaissance Technologies
New York
|
+$318K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$289K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.88M |
| 2 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$2.91M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$2.1M |
| 4 |
Millennium Management
New York
|
-$1.37M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$1.07M |
ATRS Hedge Fund Activity: Q3 2014 in Review
82 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2014, worth a combined $76.7M — down 38% from $123M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ATRS and 11 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 24 added.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $2.4M. The largest seller was Deerfield Management, cutting an estimated $3.88M.
- 82 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2014, down from 85 in Q2 2014.
- Funds reported $76.7M of Antares Pharma, Inc. stock for Q3 2014, down 38% quarter-over-quarter.
- 11 funds opened new Antares Pharma, Inc. positions in Q3 2014 and 14 closed out, a net change of -3 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2014 was Ghost Tree Capital, an estimated $2.4M added.
- The largest Antares Pharma, Inc. seller in Q3 2014 was Deerfield Management, an estimated $3.88M sold.
Based on aggregated 13F filings for Q3 2014.